Form 4: BioMarin Director Dere Willard H. Acquires 6,650 Shares of Common Stock
SEC Form 4 Filing
Director Dere Willard H. acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.
Summary
- On May 20, 2025, Dere Willard H., a director of BioMarin Pharmaceutical Inc., acquired 6,650 shares of common stock.
- The acquisition was in the form of restricted stock units (RSUs).
- Following the transaction, Dere Willard H. beneficially owns 38,950 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, simply reporting a transaction.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment as it indicates a director's continued investment in the company.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of transaction: Dere Willard H. acquired 6,650 shares of common stock through restricted stock units. |
| 05/22/2025 | Date of signature on the SEC Form 4 filing. |
Keywords
BioMarin Pharmaceutical Inc, BMRN, Dere Willard H, Director, Common Stock, Restricted Stock Units, RSU, Beneficial Ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.